Holen Sie sich die Stockscreener-App
790.74
0.70%
-5.60
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types - GlobeNewswire Inc.
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
RBC raises target for Regeneron stock to USD 810.00 - ad-hoc-news.de
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Regeneron reports 84-week Phase III data for Pasatru in adult FOP - Yahoo Finance
Regeneron reports Pasatru data and Citi holds Regeneron stock - ad-hoc-news.de
Regeneron presents new long-term data for Pasatru - The Pharma Letter
Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95 - ad-hoc-news.de
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron’s New Drug Halts Rogue Bone Growth EffectivelyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP - Quiver Quantitative
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month - Stocktwits
Should Alliance Expansion Require Action From Regeneron (REGN) Investors? - Simply Wall Street
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia
Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative - Simply Wall Street
Why Regeneron (REGN) is a Top Value Stock for the Long-Term - Zacks Investment Research
Regeneron Pharma Is Maintained at Sector Perform by RBC Capital - Moomoo
What Is Going On With Regeneron Stock? - Trefis
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD - Zacks Investment Research
Royal Bank Of Canada Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
REGN Maintains Buy Rating -- Price Target Raised to $780 by Trui - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Truist Financial - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Regeneron stock gains 1.17 percent as oncology data advances - AD HOC NEWS
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN) - Yahoo! Finance Canada
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 - Investing News Network
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $950.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Regeneron sees nearly $0.18 per share earnings headwind (REGN) - Seeking Alpha
Regeneron to Present Late-Breaking ESMO 2026 Data on Libtayo in High-Risk CSCC and Cancer-Associated Thrombosis - Quiver Quantitative
Argus upgrades Regeneron stock to Buy with USD 850.00 target - ad-hoc-news.de
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 - GlobeNewswire Inc.
Press Release : Availability of the aide-mémoire for Q3 2026 results - GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire » - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion - simplywall.st
How Investors Are Reacting To Regeneron Pharmaceuticals (REGN) Sanofi Alliance Expansion - simplywall.st
Regeneron: The Easy Money Has Been Made (Rating Downgrade) (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion - simplywall.st
Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion - Simply Wall Street
Regeneron Pharmaceuticals, Inc. (REGN) Stock forecasts - Yahoo Finance UK
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial DataRegeneron Pharmaceuticals - Benzinga
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
7.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):